GT201200011A - Diferenciación de células madre mesenquimales - Google Patents

Diferenciación de células madre mesenquimales

Info

Publication number
GT201200011A
GT201200011A GT201200011A GT201200011A GT201200011A GT 201200011 A GT201200011 A GT 201200011A GT 201200011 A GT201200011 A GT 201200011A GT 201200011 A GT201200011 A GT 201200011A GT 201200011 A GT201200011 A GT 201200011A
Authority
GT
Guatemala
Prior art keywords
mesenquimal
differentiation
mother cells
mother
cells
Prior art date
Application number
GT201200011A
Other languages
English (en)
Spanish (es)
Inventor
Johnson Kristen
Jennings Lori
Schultz Peter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200011(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200011A publication Critical patent/GT201200011A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GT201200011A 2009-07-14 2012-02-09 Diferenciación de células madre mesenquimales GT201200011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
GT201200011A true GT201200011A (es) 2013-12-10

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200011A GT201200011A (es) 2009-07-14 2012-02-09 Diferenciación de células madre mesenquimales

Country Status (30)

Country Link
US (4) US9139633B2 (instruction)
EP (1) EP2453921B1 (instruction)
JP (1) JP5602850B2 (instruction)
KR (3) KR101590834B1 (instruction)
CN (2) CN105601728B (instruction)
AU (1) AU2010273570B2 (instruction)
BR (1) BR112012000914B8 (instruction)
CA (1) CA2767826C (instruction)
CL (1) CL2012000091A1 (instruction)
CO (1) CO6491059A2 (instruction)
CR (1) CR20120024A (instruction)
CU (1) CU24042B1 (instruction)
EA (1) EA023073B1 (instruction)
EC (1) ECSP12011604A (instruction)
ES (1) ES2541217T3 (instruction)
GT (1) GT201200011A (instruction)
IL (2) IL217383A (instruction)
IN (1) IN2012DN00572A (instruction)
MA (1) MA33423B1 (instruction)
MX (1) MX2012000707A (instruction)
MY (1) MY160951A (instruction)
NZ (1) NZ597306A (instruction)
PE (2) PE20160507A1 (instruction)
PL (1) PL2453921T3 (instruction)
PT (1) PT2453921E (instruction)
SG (1) SG177318A1 (instruction)
TN (1) TN2011000655A1 (instruction)
UA (1) UA104031C2 (instruction)
WO (1) WO2011008773A2 (instruction)
ZA (1) ZA201200078B (instruction)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601728B (zh) * 2009-07-14 2020-01-10 斯克里普斯研究所 间充质干细胞分化
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN110198441B (zh) 2011-11-08 2022-01-11 韩国电子通信研究院 用于共享候选者列表的方法和装置
CN104619727B (zh) * 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JP6579623B2 (ja) 2013-03-15 2019-09-25 ザ・スクリップス・リサーチ・インスティテュート 軟骨形成を誘導するための化合物及び方法
AU2015259403B2 (en) 2014-05-13 2017-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
EP3423157A1 (en) 2016-03-03 2019-01-09 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
CA3043667A1 (en) * 2016-11-14 2018-05-17 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
WO2020115684A1 (en) 2018-12-06 2020-06-11 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
WO2020115683A1 (en) 2018-12-06 2020-06-11 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1159419A1 (en) 1999-03-08 2001-12-05 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
CA2375458A1 (en) 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
DE60141236D1 (de) * 2000-10-16 2010-03-18 Genentech Inc Behandlungsverfahren unter Verwendung von WISP-Polypeptiden
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
RS20050202A (en) * 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
EP1860186B1 (en) * 2003-03-10 2010-11-17 Japan Science And Technology Agency Method for distinguishing mesenchymal stem cells using different markers
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
CA2571315C (en) * 2004-06-21 2017-02-14 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
CN105601728B (zh) * 2009-07-14 2020-01-10 斯克里普斯研究所 间充质干细胞分化
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation

Also Published As

Publication number Publication date
CL2012000091A1 (es) 2012-10-26
US9139633B2 (en) 2015-09-22
EP2453921A4 (en) 2012-12-19
CO6491059A2 (es) 2012-07-31
EA201200118A1 (ru) 2012-09-28
US10064918B2 (en) 2018-09-04
US20190000922A1 (en) 2019-01-03
US20120177644A1 (en) 2012-07-12
PE20120570A1 (es) 2012-05-19
UA104031C2 (uk) 2013-12-25
MY160951A (en) 2017-03-31
WO2011008773A3 (en) 2011-08-25
CN102625830B (zh) 2016-03-02
BR112012000914A8 (pt) 2017-12-19
PT2453921E (pt) 2015-09-25
ES2541217T3 (es) 2015-07-16
KR20180000337A (ko) 2018-01-02
EA023073B1 (ru) 2016-04-29
WO2011008773A2 (en) 2011-01-20
KR20160015403A (ko) 2016-02-12
MX2012000707A (es) 2012-03-21
CN105601728B (zh) 2020-01-10
HK1164169A1 (en) 2012-09-21
PE20160507A1 (es) 2016-05-20
KR20120029472A (ko) 2012-03-26
BR112012000914B1 (pt) 2021-04-06
JP5602850B2 (ja) 2014-10-08
CA2767826A1 (en) 2011-01-20
CR20120024A (es) 2012-06-11
ECSP12011604A (es) 2012-06-29
BR112012000914B8 (pt) 2021-05-25
CN102625830A (zh) 2012-08-01
US20160213748A1 (en) 2016-07-28
AU2010273570A1 (en) 2012-02-02
US20200108122A1 (en) 2020-04-09
PL2453921T3 (pl) 2015-11-30
CU24042B1 (es) 2014-11-27
CA2767826C (en) 2015-11-24
US10555990B2 (en) 2020-02-11
IL217383A (en) 2016-08-31
CU20120007A7 (es) 2013-02-26
MA33423B1 (fr) 2012-07-03
SG177318A1 (en) 2012-03-29
ZA201200078B (en) 2013-01-30
AU2010273570B2 (en) 2014-07-03
NZ597306A (en) 2014-03-28
TN2011000655A1 (en) 2013-05-24
IL247310B (en) 2018-04-30
US11241482B2 (en) 2022-02-08
BR112012000914A2 (pt) 2017-08-08
CN105601728A (zh) 2016-05-25
KR101590834B1 (ko) 2016-02-12
JP2012533549A (ja) 2012-12-27
EP2453921A2 (en) 2012-05-23
IL217383A0 (en) 2012-02-29
EP2453921B1 (en) 2015-05-27
IN2012DN00572A (instruction) 2015-06-12

Similar Documents

Publication Publication Date Title
GT201200011A (es) Diferenciación de células madre mesenquimales
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
BR112014019233A2 (pt) emplastros medicinais para criar ou manter uma área de tecido humano livre de contaminantes
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
BR112012018986A2 (pt) sistemas e métodos para redução de lodos produzidos por estações de tratamento de águas residuais
PT2613774T (pt) Combinação de fenoxibenzamina e polimixina e para tratar infeções microbianas
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
ECSP11011542A (es) Composiciones farmacéuticas sólidas y procesos para su producción
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
CR20140576A (es) Sintesis de compuestos heterociclicos
BR112012002117A2 (pt) composições poliméricas modificadas de ácido hialurônico e métodos relacionados.
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
BR112013022813A2 (pt) diaminocarbonitrila pirimidinas e diaminocarboxamida substituída, composições das mesmas e métodos de tratamento com as mesmas
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
FR2990348B1 (fr) Composition et procede de soin cosmetique utilisant un melange elastique
BR112012028514A2 (pt) composição para o tratamento da água residual e processo para o tratamento de água residual
PT2909317T (pt) Métodos e composições para tratamento e controlo de doenças de plantas
MX391043B (es) Formulaciones de anticuerpo y metodos.
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
BR112013002319A2 (pt) compostos e métodos para reparo da pele
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias